Highlights Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-05-10 EDT			5-day change	1st Jan Change
15.49 ^AUD	+0.91%		+1.64%	+53.67%

05-03	Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP	MT
04-30	Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP	05-02	MT
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024	04-17	CI
Telix Pharmaceuticals Logs Nearly $115 Million Revenue in Q1	04-17	MT
Telix Pharmaceuticals Limited Announces FDA Fast Track Designation for TLX101-CDx	04-15	CI
Telix Pharmaceuticals Completes Acquisition of Canadian Firm ARTMS	04-11	MT
Telix Pharmaceuticals Limited completed the acquisition of ARTMS, INC.	04-10	CI
Telix Pharmaceuticals Completes Acquisition of IsoTherapeutics Group	04-08	MT
Telix Pharmaceuticals Limited completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.	04-08	CI
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent	03-25	CI
Telix Pharmaceuticals to Buy Canadian Radioisotope Production Firm ARTMS	03-04	MT
Telix Pharmaceuticals Limited signed an agreement to acquire ARTMS, INC. for approximately $84 million.	03-03	CI
Telix Pharmaceuticals Jumps 7% on IsoTherapeutics Group Acquisition Deal	02-26	MT
Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.	02-25	CI
Telix Pharmaceuticals Posts 214% Surge in FY23 Revenue; Returns to Profit	02-22	MT
Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024	02-22	CI
Telix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Telix Pharmaceuticals to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform	02-07	MT
Australia's Telix Pharmaceuticals jumps on potential US listing	01-04	RE
Telix Pharmaceuticals Mulls US IPO	01-04	MT
Telix Pharmaceuticals Files Biologics License Application with US FDA for Cancer Imaging Agent	12-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Highlights

Filters